An optimised dosing regimen versus a standard dosing regimen of vancomycin for the treatment of late onset sepsis due to Gram-positive microorganisms in neonates and infants aged less than 90 days (NeoVanc): study protocol for a randomised controlled trial

BACKGROUND: Vancomycin has been used in clinical practice for over 50 years; however, validated, pharmacokinetic (PK) data relating clinical outcomes to different dosing regimens in neonates are lacking. Coagulase negative staphylococci (CoNS) are the most commonly isolated organisms in neonatal, la...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Louise F., Turner, Mark A., Lutsar, Irja, Heath, Paul T., Hardy, Pollyanna, Linsell, Louise, Jacqz-Aigrain, Evelyne, Roilides, Emmanuel, Sharland, Mike
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158076/
https://www.ncbi.nlm.nih.gov/pubmed/32293527
http://dx.doi.org/10.1186/s13063-020-4184-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158076/
https://www.ncbi.nlm.nih.gov/pubmed/32293527
http://dx.doi.org/10.1186/s13063-020-4184-8

Ejemplares similares